Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Orbital Diseases Clear all
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
Interventions
linsitinib
Drug
Lead sponsor
Sling Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Miami, Florida • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced May 21, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Interventions
TEPEZZA, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced May 21, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Efgartigimod PH20 SC, Placebo PH20 SC
Combination Product · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced May 21, 2026, 8:15 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Graves' Disease
Interventions
Radiotherapy, Sham treatment
Radiation
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
30 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1998
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced May 21, 2026, 8:15 PM EDT
Approved For Marketing No phase listed Expanded access
View directory record Official record
Conditions
Thyroid Eye Disease, Graves' Orbitopathy
Interventions
Teprotumumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
U.S. locations
8
States / cities
Beverly Hills, California • Miami, Florida • Skokie, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced May 21, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Thyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease, Hyperparathyroidism
Interventions
Superficial Cervical Plexus Block, Local Wound Infiltration, 0.9% saline, Marcaine
Procedure · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced May 21, 2026, 8:15 PM EDT
Enrolling by invitation Phase 2 Interventional
View directory record Official record
Conditions
Graves' Disease
Interventions
IMVT-1402
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
89
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 75 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 8:15 PM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Graves Disease, Hashimoto Disease
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced May 21, 2026, 8:15 PM EDT
Suspended Phase 2 Interventional
View directory record Official record
Conditions
Graves Disease
Interventions
WP1302, WP1302 placebo, methimazole
Drug · Combination Product
Lead sponsor
Worg Biotherapeutics Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Hunt, Arizona • Canoga Park, California • Littleton, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced May 21, 2026, 8:15 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Graves Disease
Interventions
BHV-1300
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
South Gate, California • Miami, Florida • Columbus, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 8:15 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Graves' Dysthyroid Ophthalmopathy, Thyroid Related Orbitopathy
Interventions
Rituximab
Drug
Lead sponsor
Silkiss, Rona Z., M.D., FACS
Individual
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Oakland, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced May 21, 2026, 8:15 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced May 21, 2026, 8:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Thyroid-associated Ophthalmopathy
Interventions
Rituximab, Saline, Methylprednisolone
Drug
Lead sponsor
Rebecca Bahn
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced May 21, 2026, 8:15 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Veligrotug (VRDN-001), Placebo
Drug
Lead sponsor
Viridian Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
23
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced May 21, 2026, 8:15 PM EDT
Completed No phase listed Observational Results available
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Coronary Orbital Atherectomy plus Stenting
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Chandler, Arizona • Coon Rapids, Minnesota • Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced May 21, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Graves' Disease
Interventions
RAI treatment, ATD Group
Radiation · Drug
Lead sponsor
University of Florida
Other
Eligibility
Up to 18 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced May 21, 2026, 8:15 PM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Observational cohort study, Batoclimab
Other · Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Glendora, California • Aurora, Colorado • Livonia, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced May 21, 2026, 8:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Scleritis, Orbital Disease
Interventions
Rituximab
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced May 21, 2026, 8:15 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Graves' Disease
Interventions
IMVT-1402, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
64
States / cities
Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 8:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies
Interventions
Use of Rare Beauty makeup products
Other
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced May 21, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Teprotumumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced May 21, 2026, 8:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
Interventions
SNP analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced May 21, 2026, 8:15 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Graves Disease, Hyperthyroidism
Interventions
Potassium Iodide
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced May 21, 2026, 8:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Bioavailability, Bioequivalence
Interventions
TEPEZZA, EDP
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced May 21, 2026, 8:15 PM EDT